Business
Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program
NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that
About this update from Ovid Therapeutics Inc.
[{"type":"text","content":"NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced it will host an educational webinar on Thursday, October 22, at 1:00 p.m. ET to review multiple aspects of Angelman syndrome, including its biological mechanism, and the Company’s OV101 (gaboxadol) development program. The webinar will feature external experts discussing topics that includes the role of tonic inhibition, treatment practice in Angelman syndrome, measurement scales and what to expect from the pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome.\n Webinar Agenda & Presenters: Welcome and IntroductionJeremy M. Levin, DPhil, MB BChir – Chairman and Chief Executive Officer at Ovid Therapeutics Tonic Inhibition, Angelman Syndrome, and OV101Matthew During, M.D., DsC, FACP, FRACP – Founder of Ovid TherapeuticsTreating a Patient with Angelman SyndromeChristopher Keary, M.D. – Child, Adolescent and Adult Psychiatrist, Massachusetts General Hospital for ChildrenThe Importance of Clinical Global Impressions of Improvement (CGI-I)Judith Jaeger, Ph.D., MPA – President & Principal Scientist, CognitionMetrics, LLCOV101 in Angelman Syndrome, Clinical Results and What to Expect from NEPTUNEAmit Rakhit, M.D., MBA – President and Chief Medical Officer at Ovid TherapeuticsCompelling Market OpportunityJason Tardio – Chief Commercial Officer at Ovid Therapeutics Webinar Registration & InformationDate: Thursday, October 22Time: 1:00 p.m. ET The live webinar can be accessed on the Events & Presentations section of the Company's website at https://investors.ovidrx.com/news-events/presentations-events. An archived replay will be available on the Company's website following the live event. About OV101 (gaboxadol) OV101 (gaboxadol) is a delta (δ)-selective GABAA receptor agonist in clinical development for the potential treatment of two rare neurodevelopmental conditions: Angelman syndrome and Fragile X syndrome. These receptors are thought to have a central role in tonic inhibition, a key physiological process of the brain believed to be a core pathophysiology underlying certain neurodevelopmental disorders. We believe OV101 is the first and only investigational drug to specifically target the disruption of ...